Total Payments
$241,679
2024 Payments
$203,909
Companies
13
Transactions
89
Payment Breakdown by Category
Research$233,705 (96.7%)
Travel$4,135 (1.7%)
Food & Beverage$3,839 (1.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $233,705 | 20 | 96.7% |
| Travel and Lodging | $4,135 | 21 | 1.7% |
| Food and Beverage | $3,839 | 48 | 1.6% |
Payments by Type
Research
$233,705
20 transactions
General
$7,974
69 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $232,457 | 15 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $2,010 | 17 | $0 (2023) |
| Biogen, Inc. | $1,627 | 10 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,503 | 12 | $0 (2018) |
| Acorda Therapeutics, Inc | $1,431 | 6 | $0 (2017) |
| F. Hoffmann-La Roche AG | $1,292 | 5 | $0 (2024) |
| Eisai Inc. | $978.29 | 18 | $0 (2024) |
| Lilly USA, LLC | $119.27 | 1 | $0 (2024) |
| Sumitomo Pharma America, Inc. | $99.01 | 1 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $94.58 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $203,909 | 12 | Eli Lilly and Company ($203,285) |
| 2023 | $735.29 | 6 | Eli Lilly and Company ($435.75) |
| 2022 | $9,337 | 19 | Eli Lilly and Company ($7,563) |
| 2021 | $183.97 | 3 | Eli Lilly and Company ($168.38) |
| 2020 | $2,331 | 3 | Eli Lilly and Company ($2,310) |
| 2019 | $10,555 | 14 | Eli Lilly and Company ($9,591) |
| 2018 | $11,020 | 14 | Eli Lilly and Company ($9,069) |
| 2017 | $3,607 | 18 | Acorda Therapeutics, Inc ($1,431) |
All Payment Transactions
89 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/13/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | Cash or cash equivalent | $119.27 | General |
| Category: Neuroscience | ||||||
| 10/31/2024 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $65.99 | General |
| 10/31/2024 | UCB SA | — | Food and Beverage | In-kind items and services | $25.64 | General |
| 10/30/2024 | F. Hoffmann-La Roche AG | — | Food and Beverage | In-kind items and services | $54.14 | General |
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $203,285.00 | Research |
| Study: A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) | ||||||
| 09/04/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $24.78 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 07/31/2024 | F. Hoffmann-La Roche AG | — | Food and Beverage | In-kind items and services | $70.70 | General |
| 07/29/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $30.45 | General |
| Category: Oncology | ||||||
| 07/28/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $94.58 | General |
| 07/28/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $17.71 | General |
| 04/18/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $99.01 | General |
| Category: HORMONE THERAPY | ||||||
| 02/10/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $21.82 | General |
| Category: Oncology | ||||||
| 08/21/2023 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $22.51 | General |
| Category: Oncology | ||||||
| 01/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $300.00 | Research |
| Study: A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | ||||||
| 01/17/2023 | JAZZ PHARMACEUTICALS INC. | SUVECALTAMIDE | Travel and Lodging | Cash or cash equivalent | $242.50 | General |
| 01/17/2023 | JAZZ PHARMACEUTICALS INC. | SUVECALTAMIDE | Travel and Lodging | Cash or cash equivalent | $15.00 | General |
| 01/14/2023 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $19.53 | General |
| Category: Oncology | ||||||
| 01/10/2023 | Eli Lilly and Company | — | — | In-kind items and services | $135.75 | Research |
| Study: A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | ||||||
| 12/22/2022 | JAZZ PHARMACEUTICALS INC. | — | Travel and Lodging | Cash or cash equivalent | $236.22 | General |
| 12/22/2022 | JAZZ PHARMACEUTICALS INC. | — | Food and Beverage | In-kind items and services | $50.84 | General |
| 12/22/2022 | JAZZ PHARMACEUTICALS INC. | — | Travel and Lodging | Cash or cash equivalent | $15.00 | General |
| 12/09/2022 | JAZZ PHARMACEUTICALS INC. | — | Travel and Lodging | Cash or cash equivalent | $271.37 | General |
| 12/09/2022 | JAZZ PHARMACEUTICALS INC. | — | Travel and Lodging | Cash or cash equivalent | $271.37 | General |
| 12/09/2022 | JAZZ PHARMACEUTICALS INC. | — | Food and Beverage | In-kind items and services | $89.13 | General |
| 12/09/2022 | JAZZ PHARMACEUTICALS INC. | — | Food and Beverage | In-kind items and services | $89.13 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) | Eli Lilly and Company | $203,285 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $19,478 | 5 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $5,713 | 1 |
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $1,579 | 2 |
| ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $1,492 | 1 |
| 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease | Biogen, Inc. | $1,422 | 7 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $300.00 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $300.00 | 1 |
| A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | Eli Lilly and Company | $135.75 | 1 |
About Dr. Mark Goldstein, MD
Dr. Mark Goldstein, MD is a Neurology healthcare provider based in Atlantis, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1013952282.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Goldstein, MD has received a total of $241,679 in payments from pharmaceutical and medical device companies, with $203,909 received in 2024. These payments were reported across 89 transactions from 13 companies. The most common payment nature is "" ($233,705).
Ad
Practice Information
- Specialty Neurology
- Location Atlantis, FL
- Active Since 06/19/2006
- Last Updated 10/03/2007
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1013952282
Products in Payments
- Non-Covered Product (Drug) $1,167
- CNP520 (Drug) $613.91
- ARZERRA (Drug) $604.20
- SUVECALTAMIDE $257.50
- Lenvima (Drug) $152.73
- KISUNLA (Drug) $119.27
- ORGOVYX (Drug) $99.01
- BOTOX (Biological) $24.78
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Atlantis
Jose Labault-Santiago, M.d, M.D
Neurology — Payments: $8,889
Neurology $8,889
Teresita Casanova, M.d, M.D
Neurology — Payments: $8,760
Neurology $8,760
Casandra Mateo, M.d, M.D
Neurology — Payments: $8,571
Neurology $8,571
Eric Kramer, Md, MD
Neurology — Payments: $6,182
Neurology $6,182
James Goldenberg, Md, MD
Neurology — Payments: $1,012
Neurology $1,012
Dr. Yvonne Jurcik, M.d, M.D
Neurology — Payments: $134.36
Neurology $134.36